The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.Last month HIMA passed a
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.
Last month HIMA passed a resolution reminding companies to use the third-party review system. HIMA represents more than 800 manufacturers of medical devices, diagnostic products, and medical information systems.
The Food and Drug Administration Modernization Act, passed three years ago, devised the third-party system in response to a growing backlog of FDA applications and a dearth of personnel to complete the reviews. The act created a group of scientific and industry experts qualified to grant FDA approval for medical devices, said Linda Ruckel, HIMA spokeswoman.
HIMA members may be hesitant to use the third-party review system for product approval because they arent used to it, Ruckel said.
We believe its a good thing. A lot of times (members) will go for the old tried and true way rather than a new format, Ruckel said. We know its out there and we want to encourage (companies) to use it more.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.